Oppenheimer Maintains Outperform on United Therapeutics

Oppenheimer is out with its report today on United Therapeutics UTHR, maintaining Outperform. In a note to clients, Oppenheimer writes, "We believe UTHR's revenue/EPS growth rate will substantially exceed almost all mid- and large-cap biotech peers' in 2010-2013. We expect the robust launch of Tyvaso to continue, and also expect stable Remodulin sales in the long term. Importantly, we expect launch of oral treprostinil in early 2013, which should further fuel UTHR's long-term growth. We believe UTHR is poised to deliver best-in-class 2010-2013 EPS CAGR, given our assumptions about revenue growth for the company's PAH franchise and the company's considerable operating leverage." Oppenheimer maintains a $77 PT on UTHR. Shares of UTHR closed Tuesday at $54.28, up 0.99% from Tuesday's close.